Dr Yael Cohen speaks to ecancer at the ASH 2019 meeting in Orlando about results from the KyDaR trial,
She explains that the multi-centre trial uses the quadruple combination of carfilzomib, lenalidomide, dexamethasone and daratumumab (KRD-D) for induction resistant myeloma, along with conducting translational single-cell analysis.
Dr Cohen reports that not only did the patients show deep and sustained responses to the combination, but the trial also identified potential drivers of advanced resistance, including novel immune checkpoints.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.